Abstract
Objective: To assess the five- and ten-year cardiovascular disease risk in HIV-positive patients on antiretroviral therapy,using the Framingham risk score and the Data collection on adverse effects of anti-HIV drugs (D:A:D) study. Materials and methods: An observational prospective cross-sectional study. HIV-positive patients on antiretroviraltreatment from a referral center for HIV patients were included in the study between January 1 and April 30, 2019. Afive- and ten-year cardiovascular risk assessment was performed using the Framingham risk score and the D:A:D study.Additionally, both risk models were compared through statistical models. Results: The study population consisted of 159 patients with a mean age of 48.90 years ± 9.90. The mean cardiovascular riskaccording to the five-year Framingham risk score was 2.70 % ± 2.80, the ten-year Framingham risk score was 6.10 % ± 5.70,the five-year D:A:D study was 3.50 % ± 4.10, the ten-year D:A:D study was 6.90 % ± 7.70, and the ten-year Framingham riskscore recalculated for Colombia (multiplied by 0.75) was 4.50 % ± 4.20. Using a logistic regression model, it was determinedthat the ten-year D:A:D study provided the greatest number of variables significantly related to a high cardiovascular risk. Conclusions: The study showed a significant difference between the risk models. Both the five- and ten-year D:A:D studyprovided a better cardiovascular disease risk estimation than the five- and ten-year Framingham model.
Highlights
The mean cardiovascular risk according to the five-year Framingham risk score was 2.70 % ± 2.80, the ten-year Framingham risk score was 6.10 % ± 5.70, the five-year D:A:D study was 3.50 % ± 4.10, the ten-year D:A:D study was 6.90 % ± 7.70, and the ten-year Framingham risk score recalculated for Colombia was 4.50 % ± 4.20
Using a logistic regression model, it was determined that the ten-year D:A:D study provided the greatest number of variables significantly related to a high cardiovascular risk
The study showed a significant difference between the risk models
Summary
Diferencias entre los modelos de riesgo Framingham y DAD en la evaluación del riesgo cardiovascular en pacientes con VIH bajo terapia antirretroviral: experiencia en una población del caribe colombiano. Objetivo: Evaluar el riesgo de enfermedad cardiovascular a cinco y a diez años en pacientes con infección por VIH en terapia antirretroviral, por medio de las escalas Framingham y Data collection on Adverse Effects of Anti-HIV Drugs Study. Se realizó evaluación del riesgo cardiovascular a cinco y a diez años a través de los modelos de predicción de Framingham y la escala Data collection on Adverse Effects of Anti-HIV Drugs Study (DAD), y una comparación entre ellos a través de modelos estadísticos. Conclusiones: El estudio evidenció una diferencia significativa, con mayor riesgo estimado de enfermedad cardiovascular al utilizar el modelo DAD en comparación con el Framingham, tanto para la estimación a cinco años como a diez. Differences between the Framingham and D:A:D risk models for cardiovascular risk assessment in HIV-positive patients on antiretroviral therapy: an experience in a Colombian Caribbean population
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
